Roche has signed a definitive merger agreement to acquire Anadys Pharmaceuticals, a manufacturer of antiviral drug compunds, for a total cash consideration of approximately $230m.
As per the merger agreement, Roche will acquire all the outstanding shares of Anadys’ common stock at a price of $3.70 per share in cash.
Anadys president and CEO Steve Worland said Roche’s capabilities and experience in HCV would provide the best chance of success for the new potential treatments to reach hepatitis C patients.
Roche Pharma Research and Early Development global head Jean-Jacques said the aim of this transaction is to offer physicians and hepatitis patients a powerful combination of therapies that bring them closer to a cure, even without the use of interferon.
"Anadys’ compounds provide additional modes of action that could lead to interferon-free treatment regimens without viral resistance," Jacques added.